/apple-app-store.png?width=97&name=apple-app-store.png)
/google-play.png?width=88&name=google-play.png)
December 21, 2022 at 2:30 PM
A 13-page Quarterly Update is now available on Bioxytran, Inc., a clinical stage pharmaceutical company developing therapeutics in two areas: (1) glycovirology and anti-viral therapeutics; and (2) hypoxic conditions, necrosis, and degenerative diseases.
Topics: covid19, coronovirus, SARS-CoV-2, galectrin-3, glycovirology, bioxytran, complex carbohydrate chemistry, galectin
August 25, 2022 at 8:46 PM
An Executive Informational Overview (EIO) is now available on Bioxytran, Inc., a clinical stage pharmaceutical company developing therapeutics in two areas: (1) glycovirology and anti-viral therapeutics; and (2) hypoxic conditions, necrosis, and degenerative diseases. The 70-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.
Topics: covid19, coronovirus, SARS-CoV-2, galectrin-3, glycovirology, bioxytran, complex carbohydrate chemistry, galectin
May 18, 2022 at 11:06 AM
An Executive Informational Overview (EIO) is now available on ImmunoPrecise Antibodies Ltd, a full-service contract research organization (CRO) for therapeutic antibody discovery and development. The 72-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.
Topics: biotech, biopharmaceuticals, biotechnology, Oncology, Biologics, Humanized monoclonal antibodies, Immunoassay, Immunogen, Monoclonal antibody, Antibody, Contract research organization (CRO), Customer relationship management (CRM), Human monoclonal antibodies, SARS-CoV-2, Polyclonal antibody, Contract manufacturing organization (CMO), Enterprise resource planning (ERP)
/facebook.png)
FACEBOOK/twitter.png)
TWITTER/youtube.png)
YOUTUBE/linkedin.png)
LINKEDIN/slideshare.png)
SLIDESHARE/rss.png)
RSS